GLAUKOS CORP (GKOS) Stock Price, Forecast & Analysis
USA - New York Stock Exchange - NYSE:GKOS - US3773221029 - Common Stock
GKOS Key Statistics, Chart & Performance
The current stock price of GKOS is 119.87 USD. In the past month the price increased by 0.63%. In the past year, price decreased by -26.8%.
GKOS Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to GKOS. When comparing the yearly performance of all stocks, GKOS turns out to be only a medium performer in the overall market: it outperformed 46.77% of all stocks.
GKOS Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to GKOS. GKOS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
GKOS Financial Highlights
Over the last trailing twelve months GKOS reported a non-GAAP Earnings per Share(EPS) of -1.02. The EPS increased by 52.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -8.77% | ||
| ROE | -11.39% | ||
| Debt/Equity | 0.09 |
GKOS Forecast & Estimates
22 analysts have analysed GKOS and the average price target is 126.19 USD. This implies a price increase of 5.27% is expected in the next year compared to the current price of 119.87.
For the next year, analysts expect an EPS growth of 55.29% and a revenue growth 30.18% for GKOS
GKOS Ownership
GKOS Latest News, Press Relases and Analysis
GKOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 24.48 | 212.42B | ||
| ISRG | INTUITIVE SURGICAL INC | 62.03 | 189.34B | ||
| SYK | STRYKER CORP | 27.6 | 138.99B | ||
| BSX | BOSTON SCIENTIFIC CORP | 29.99 | 131.17B | ||
| BDX | BECTON DICKINSON AND CO | 14.43 | 59.39B | ||
| IDXX | IDEXX LABORATORIES INC | 56.88 | 57.27B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.82 | 48.95B | ||
| RMD | RESMED INC | 26.18 | 37.83B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 17.74 | 37.09B | ||
| DXCM | DEXCOM INC | 37.63 | 27.30B | ||
| PODD | INSULET CORP | 62.77 | 20.18B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.84 | 17.38B |
Related stock screener links
About GKOS
Company Profile
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 995 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Company Info
GLAUKOS CORP
1 Glaukos Way
Aliso Viejo CALIFORNIA 92672 US
CEO: Thomas W. Burns
Employees: 995
Phone: 19493679600
GLAUKOS CORP / GKOS FAQ
Can you describe the business of GLAUKOS CORP?
Glaukos Corp. is an ophthalmic medical technology and pharmaceutical company, which focuses on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. The company is headquartered in Aliso Viejo, California and currently employs 995 full-time employees. The company went IPO on 2015-06-25. The firm is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
What is the current price of GKOS stock?
The current stock price of GKOS is 119.87 USD. The price increased by 4.71% in the last trading session.
Does GLAUKOS CORP pay dividends?
GKOS does not pay a dividend.
How is the ChartMill rating for GLAUKOS CORP?
GKOS has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What do analysts say about GLAUKOS CORP (GKOS) stock?
22 analysts have analysed GKOS and the average price target is 126.19 USD. This implies a price increase of 5.27% is expected in the next year compared to the current price of 119.87.
What sector and industry does GLAUKOS CORP belong to?
GLAUKOS CORP (GKOS) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
What is the Short Interest ratio of GLAUKOS CORP (GKOS) stock?
The outstanding short interest for GLAUKOS CORP (GKOS) is 3.69% of its float.